AUS-131

At Ausio, we are working to discover and develop products to improve the lives of the aging population. Our lead compound, AUS-131, is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor α (ERα). Completed Phase 1 studies have demonstrated that AUS-131 is safe and well tolerated in humans. Phase 2a trials in menopausal women with vasomotor symptoms (VMS) and men with benign prostatic hyperplasia (BPH) are ongoing and are expected to be completed in 2011.

For more information relating to Ausio’s product pipeline and partnering opportunities, click here.

Patents

Ausio has rapidly garnered a strong patent position for AUS-131.

US 7,396,855

Issued July 8, 2008 (Expiry December 3, 2024)
Composition and Products Containing S-equol, and Methods for their Making

US 7,528,267

Issued May 5, 2009 (Expiry January 27, 2027)
Method for Enantioselective Hydrogenation of Chromenes

AUS 2002359220

Issued December 15, 2008 (Expiry July 24, 2023)
Compositions and Products Containing Enantiomeric equol, and Methods for their Making

China ZL03822155.1

Issued May 26, 2010 (Expiry July 24, 2023)
Compositions and Products Containing Enantiomeric equol, and Methods for their Making

Japan and EU Pending Office Action

Home Contact Us Directions